Editorial: The reawakening of bendamustine - Also in breast cancer?

Onkologie

Volumn 32, Issue 8-9, 2009, Pages 462-463

  Von Minckwitz, Gunter ^a   Linder, Mattea ^a   Loibl, Sibylle ^a  

^a GBG Forschungs GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ERLOTINIB; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RITUXIMAB; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE;

BODY SURFACE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER REGRESSION; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ACTIVITY; DISEASE CONTROL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; EDITORIAL; HODGKIN DISEASE; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; ONCOGENE NEU; OVERALL SURVIVAL; QUALITY OF LIFE; RISK REDUCTION; SAMPLE SIZE; TOXICITY; TREATMENT RESPONSE; BREAST TUMOR; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; GERMANY; HUMAN; NOTE; ONCOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; GERMANY; HUMANS; MEDICAL ONCOLOGY; NITROGEN MUSTARD COMPOUNDS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 70149106241     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229747     Document Type: Editorial

References (14)

1. Cheson BD: Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-1501.
2. Leoni ML, Bailey B, Reifert J, et al.: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14: 309-317.
3. Leoni LM, Niemeyer CC, Kerfoot C, et al.: In vitro and ex vivo activity of SDX-105 (bendamustine) in drugresistant lymphoma cells. Proc Am Assoc Cancer Res 2004;45:27, abstr 1215.
4. Rummel ML, et al.: Bendamustine plus rituximab versus CHOP with indolent and mantle-cell lym-phomas: the first interim results of a randomized phase III study of the StiL. Blood 2007;110:120a: abstr 385.
5. Kahl B, et al.: Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin's lymphoma. Blood 2007;110:406a, abstr 1351.
6. Von Minckwitz, Chernozemsky I, Sirakova L, et al.: Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate, and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as front-line treatment of MBC. Anticancer Drugs 2005;16:871-877.
7. Hoffken K, Merkle K, Schonfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S: Bendamustin as salvage treatment in patients with advanced progressive breast cancer. A phase II study. J Cancer Res Clin Oncol 1998;124:627-632.
8. Reichmann U, Bokemeyer C, Wallwiener D, et al.: Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Ann Oncol 2007;18:1981-1984.
9. Steinbild S, Frost A, Haring B, Unger C, Mross K: Phase II study with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer. Onkologie 2009;32:488-492.
10. DeJongh FE, Verweij J, Loos WJ, et al.: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19:3733-3739.
11. Baker SD, Verweij J, Rowinsky EK, et al.: Role of body surface area in dosing of investigational anti-cancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-1888.
12. Ratain MJ: Body surface area as a basis for dosing of anticancer agents: science, myth or habit? J Clin Oncol 1998;16:2297-2298.
13. Loibl S, Murmann C, Schwedler K, et al.: Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. Cancer Chemother Pharmacol 2009;63:953-958.
14. www.clinicaltrials.govidentifier:NCT00834678